Cyclopharm Stock

Detail Data
Volume (24h): 18,781 shares
P/E Ratio: /
Forward P/E: -53.25
EPS: -0.13 AUD
Forward EPS: -0.02 AUD
Number of Shares: 111,137,000 shares
Market Capitalization: 121,588,928.00 AUD

Dividend

Dividend Value
Dividend Amount According to our data, the company Cyclopharm does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: 2023-09-01
5-Year Avg Yield %: 0.59 %
Payout Ratio: -
Last Dividend Value: 0.005 AUD
Last Dividend Date: 2023-09-01

Analyst Forecast

Most analysts have issued a none recommendation for Cyclopharm stock. The current number of analysts covering this company is 1. The highest target price is 2.704876 AUD, while the lowest target price is 2.704876 AUD. The median target valuation set by analysts is 2.704876 AUD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Cyclopharm.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Cyclopharm stock is: none
Number of Analysts: 1
Highest Target Price: 2.704876 AUD
Lowest Target Price: 2.704876 AUD
Median Target Price: 2.704876 AUD

Fundamental Indicators

Indicator Data
Total Revenue: 27,572,580.00 AUD
Net Income: -13,197,618.00 AUD
Price-to-Book (P/B): 2.77
PEG Ratio: /
Exchange: ASX
Industry: Medical Distribution
Sector: Healthcare
Number of Employees: 95
Country: Australia

Where to Buy Cyclopharm Stock?

You can purchase Cyclopharm stock on the ASX under the ticker symbol: CYC.AX. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Cyclopharm Stock

Indicator Value
Company Revenue: 27,572,580.00 AUD
EBITDA: -13,689,883.00 AUD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -0.13 AUD
Book Value Per Share: 0.38 AUD
Total Cash: 20,567,898.00 AUD
Total Cash per Share: 0.19 AUD
Total Debt: 8,285,764.00 AUD
Debt to Equity Ratio: 0.19
Quick Ratio 2.54
Current Ratio 4.00
Free Cash Flow -10,206,752.00 AUD
Operating Cash Flow -12,574,405.00 AUD
Gross Margins 65.04 %
EBITDA Margins -49.65 %
Operating Margins -49.16 %
Profit Margins -47.87 %
Return on Assets -16.8 %
Return on Equity -35.2 %
Earnings Growth (1 year) -
Revenue Growth (1 year) 43.0 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 121,588,928.00 AUD
Enterprise Value 109,968,400.00 AUD
EV/Revenue 3.988
EV/EBITDA -8.033
Float Shares 56,551,986 shares
Shares Outstanding 111,137,000 shares
Held Percent Insiders 0.49 %
Held Percent Institutions 21.62 %
Shares Short -
Shares Short Prior Month -
Date Short Interest -
Short Percentage of Total Shares -
Short Ratio -
Beta 0.86
Short Percentage of Float -
Implied Shares Outstanding 114,168,000

Frequently Asked Questions (FAQ)

According to our data, the company Cyclopharm does not pay dividends yet, even in 2025.

Cyclopharm shares are traded on the ASX stock exchange under the ticker: CYC.AX. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Cyclopharm shares is from a total of 1 analysts. The average target price prediction is 2.704876 AUD per share.

The total number of Cyclopharm shares on the exchange is 111,137,000.00 shares, which at the current market capitalization gives the company a total valuation of 121,588,928.00 AUD.